Morgan D A, Gilson D, Fletcher J
Hogarth Centre of Radiotherapy and Oncology, General Hospital, Nottingham, England.
Eur J Cancer Clin Oncol. 1987 Jun;23(6):619-21. doi: 10.1016/0277-5379(87)90256-2.
Chemotherapy prolongs survival of patients with small-cell lung cancer, but very few are cured, and the treatment is unpleasant. Thirty patients, 28 with advanced disease, were treated with etoposide 250 mg/m2 orally, daily for 5 days, plus vincristine 2 mg intravenously on the first day, the cycle being repeated 3-weekly, to a maximum of 6. There was a response rate of 70%, a median survival of 249 days, and an 11% 2-year survival. Symptomatic side-effects were less pronounced than with most other regimens of comparable efficacy.
化疗可延长小细胞肺癌患者的生存期，但很少能治愈，而且治疗过程令人不适。30例患者，其中28例为晚期患者，接受依托泊苷250mg/m²口服，每日1次，共5天，加长春新碱2mg静脉注射，第1天用药，每3周重复1个周期，最多6个周期。有效率为70%，中位生存期为249天，2年生存率为11%。有症状的副作用比大多数疗效相当的其他方案要轻。
